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 We report a novel protective action of estrogen on the BBB. 
 Estrogen enhances inter-endothelial cell tight junction function. 
 Estrogen’s actions are mediated by GPR30 signalling and phosphorylation of annexin 
A1. 
 Estrogen limits lymphocyte extravasation after challenge with inflammatory cytokines. 
 Estrogen limits inflammation-induced immune cell trafficking through ERβ/annexin 
A1 pathways 
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ABSTRACT 
Sex differences have been widely reported in neuroinflammatory disorders, focusing on the 
contributory role of estrogen. The microvascular endothelium of the brain is a critical 
component of the blood-brain barrier (BBB) and it is recognised as a major interface for 
communication between the periphery and the brain. As such, the cerebral capillary 
endothelium represents an important target for the peripheral estrogen neuroprotective 
functions, leading us to hypothesise that estrogen can limit BBB breakdown following the onset 
of peripheral inflammation. 
 
Comparison of male and female murine responses to peripheral LPS challenge revealed a short-
term inflammation-induced deficit in BBB integrity in males that was not apparent in young 
females, but was notable in older, reproductively senescent females. Importantly, ovariectomy 
and hence estrogen loss recapitulated an aged phenotype in young females, which was 
reversible upon estradiol replacement. Using a well-established model of human 
cerebrovascular endothelial cells we investigated the effects of estradiol upon key barrier 
features, namely paracellular permeability, transendothelial electrical resistance, tight junction 
integrity and lymphocyte transmigration under basal and inflammatory conditions, modelled 
by treatment with TNFα and IFNγ. In all cases estradiol prevented inflammation-induced 
defects in barrier function, action mediated in large part through up-regulation of the central 
coordinator of tight junction integrity, annexin A1. The key role of this protein was then further 
confirmed in studies of human or murine annexin A1 genetic ablation models. 
 
Together, our data provide novel mechanisms for the protective effects of estrogen, and 
enhance our understanding of the beneficial role it plays in neurovascular/neuroimmune 
disease. 
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1. Introduction 
Several lines of evidence suggest that the sex differences seen in vascular and neural diseases 
may be at least partly linked to differing sex hormone complements. In particular, a number of 
beneficial effects have been attributed to the principal female hormone estrogen, including in 
conditions as diverse as Parkinson’s disease, Alzheimer’s disease, head injury and multiple 
sclerosis (1). One important working hypothesis is that the neuroprotective effects of estrogen 
may be related to its known anti-inflammatory and immunomodulatory actions (2, 3).  
 
The endothelium of the blood-brain barrier (BBB) is at the forefront of the defensive features 
of the central nervous system, regulating its interactions with the immune system. In particular, 
there is accumulating evidence that BBB function is compromised during peripheral 
inflammation, leading to inappropriate passage of cells and molecules into the brain 
parenchyma (4). Estrogen has been shown to exert a variety of anti-inflammatory effects, 
including reducing iNOS activity (5), directly regulating the cytokine milieu (6) and altering 
expression of vascular and leukocyte adhesion molecules (7). Whilst initial studies have 
identified estrogen as being able to modulate BBB tight junction proteins such as claudin 5 (8), 
full characterisation of the effects of estrogen upon the BBB is lacking, and represents an 
underexplored aspect of hormonal protection.  
 
We have previously studied the importance of the anti-inflammatory protein annexin A1 
(ANXA1) in the BBB, where it plays a major role in the regulation of tight junction expression, 
contributing to limited barrier permeability (9). Although ANXA1 was originally described as 
a glucocorticoid second messenger (10), we and others have since reported that it can also be 
modulated by estrogen (11-13), leading us to hypothesise that estrogen may exert protective 
effects upon the BBB in inflammation through the regulation of this protein. 
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Using a combined in vivo/in vitro approach, we examined the response of the BBB to peripheral 
inflammatory challenge and the ability of the principal estrogen: estradiol (E2) to restore 
homeostasis in this system. We report here the presence of sexual dimorphism in the response 
of the BBB to peripheral pro-inflammatory challenge in vivo, and a dual protective role for 
estradiol upon the inflamed cerebral endothelium in vitro, mediated through the regulation of 
ANXA1 and ICAM-1 expression. Together these actions control movement of both small 
molecules and immune cells across the cerebral endothelium. 
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2. Materials and Methods 
2.1 Reagents  
All reagents are from Sigma-Aldrich (Poole, United Kingdom) unless otherwise stated. Cell 
culture medium and solutions were purchased from Lonza (Basel, Switzerland). The ERα 
agonist PPT (4,4',4''-(4-propyl-(5)-pyrazole-1,3,5triyl) trisphenol), the ERβ agonist DPN (2,3-
bis(4-Hydroxyphenyl)-propionitrile), the GPR30 agonist G-1 ((±)-1-[(3aR*,4S*,9bS*)-4-(6-
bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-
ethanone), the ERβ antagonist PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-
a]pyrimidin-3-yl]phenol) and the GPR30 antagonist G-15 ((3aS*,4R*,9bR*)-4-(6-bromo-1,3-
benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]quinolone) were purchased from Tocris 
Bioscience (Bristol, United Kingdom). TNFα and IFNγ were purchased from R&D Systems 
(Abingdon, United Kingdom).  
 
2.2 Human Recombinant Annexin A1 production and purification 
cDNA of human ANXA1 carrying a cleavable N-terminal poly-His tag was expressed in E. 
coli. Recombinant protein was purified on IMAC (GE Healthcare), and the poly-His tag was 
subsequently removed. Purity of recombinant ANXA1 was confirmed by SDS-PAGE and the 
4800 MALDI-TOF/TOF (Applied Biosystems), revealing a 38.6-kDa protein that was >95% 
pure (9). 
 
2.3 Animal experiments 
Male and female 2 and 15 month old C57Bl/6 and AnxA1-/- mice were bred at Charles River 
under our project QMUL.ES Annexin. Female C57Bl/6 mice were sham-operated or 
ovariectomised under isofluorane anaesthesia with buprenorphine analgesia, and micro-
osmotic pumps containing either estradiol or β-cyclodextrin vehicle were implanted 
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subcutaneously (Alzet model 2002; Durect Co., Cupertino CA, USA); similar ovariectomy has 
been previously shown to significantly reduce circulating estrogen in ovariectomised animals 
when compared with sham-operated mice (14). Mice were sacrificed by exsanguination. All 
experiments were performed at the same time of day to avoid the confounding effects of 
circadian rhythm. In some experiments ovariectomised mice were further treated with 
intravenous (i.v.) human recombinant ANXA1 before further challenge with 3mg/kg 
lipopolysaccharide (LPS). 
 
2.4 In vivo assessment of BBB leakage  
Mice were injected i.p. with 3mg/kg LPS in 100µl saline vehicle and cerebrovascular 
permeability was assessed at 4 hours, 24 hours or 7 days post-injection. One hour before 
assessment animals were injected i.v. with 100µl of a 2% (w/v) solution of Evans blue dye in 
0.9% saline (Sigma-Aldrich Ltd.; Poole, United Kingdom). Dye was permitted to circulate for 
1h before animals were transcardially perfused with 0.9% saline at 4°C to remove circulating 
dye, as described previously (9); brain Evan’s blue content was expressed as µg of dye/mg of 
brain tissue, normalised to circulating plasma concentrations. 
  
2.5 Murine T lymphocyte transmigration on isolated primary microvascular brain endothelial 
cells  
Murine T cells were isolated from lymph nodes of C57BL/6 WT mice and activated for 3 days 
in 24-well plates coated with anti-CD3 (1μg/ml) and anti-CD28 (5μg/ml) antibodies 
(BioLegend), and containing IL-2 (10ng/ml; PeproTech) as previously described (15). 
Capillaries were extracted from the cortex of 3-month-old WT mice as previously described 
(9). Isolated vessels were put in culture until confluence. Primary brain microvascular 
endothelial cells were then used at passage one in 24-well plate Polycarbonate transwell inserts 
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(surface: 0.33 cm2, pore size: 5µm; Sigma-Aldrich, UK) and put in contact with murine T 
lymphocytes for the lymphocyte transmigration assay (4h at 37°C in 5% CO2) as described in 
section 2.8. 
 
2.6 hCMEC/D3 cells 
The hCMEC/D3 cell line used for in vitro and molecular analysis was maintained and treated 
as described previously (9, 16). For permeability and imaging experiments cells were either 
polarized through growth on 12-well plate Polyethylene Terephthalate (PET) transwell inserts 
(surface: 1.12 cm2, pore size: 0.4 µm; Sigma-Aldrich, UK) coated with calf-skin collagen and 
fibronectin (Sigma-Aldrich, UK), or plated on Nunc™ Lab-tek Chamber slide system 
Permanox Plastic 25x75 mm (ThermoScientific, UK). 
 
2.7 In vitro barrier function assessments  
Permeability of hCMEC/D3 cell monolayers to 70kDa FITC-dextran (3mg/ml) was measured 
as described previously (9, 17, 18). Transendothelial electrical resistance (TEER) 
measurements were performed on 100% confluent cultures using a Millicell-ERS apparatus 
(Millipore, Watford, United Kingdom) and expressed as Ω•cm2. Values obtained from cell-
free inserts were subtracted from the total values.  
 
2.8 Lymphocyte transmigration assay  
hCMEC/D3 brain endothelial cells were cultured in monolayers on 24-well plate 
Polycarbonate transwell inserts (surface: 0.33 cm2, pore size: 5µm; Sigma-Aldrich, UK) for 
48h prior to assay. After 24h, TNFα and IFNγ (10ng/ml) were added to the upper chambers; 
after 48h, and just before the assay started, 600µl of complete EGM-2 MV medium was added 
to the lower compartment. Peripheral blood mononuclear cells (PBMCs), isolated from fresh 
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venous blood of healthy volunteers by Ficoll-gradient (d=1.077 g/cm3; Sigma-Aldrich, UK), 
were added to the upper compartment (1x106 in 100 µl) and cells were incubated for 4h at 37°C 
in 5% CO2. Inserts were then removed, and the entire volume of the lower compartment was 
collected to assess transmigrated PBMCs. PBMCs adhering to monolayers were determined 
by washing inserts with D-PBS once to remove non-bound cells, and then a second time more 
vigorously with 5mM EDTA in D-PBS (4°C) for 10 minutes. Cells recovered in the EDTA 
washing step were considered the adherent cell population (19). Adherent and migrated cells 
were stained with PE-conjugated CD3+ antibody (1:200; eBioscience) and then analysed by 
flow cytometry to determine relative CD3+ T lymphocyte populations as described below.  
 
2.9 Quantification of ANXA1 by ELISA  
Total human ANXA1 was measured by specific sandwich ELISA, as described previously 
(20).  
 
2.10 Protein extraction and immunoblotting 
For ANXA1 analysis the membrane-bound fraction was extracted by EDTA-EGTA wash 
(1mM in PBS), as previously described (21); total protein extraction was performed by 3 cycles 
of freeze/thawing in RIPA buffer (1mM EDTA, 150mM NaCl, 50mM Tris⋅HCl, 1% Triton X-
100, 0.1% SDS, 1% sodium deoxycholate, protease inhibitors, pH 7.4). Protein resolution and 
visualisation was performed as previously described (9, 20, 22), using the following antibodies: 
Annexin A1 (1:5000; Invitrogen), ℗-S-Annexin A1 [1:1000; (22, 11) and GAPDH (1:5000; 
Sigma)]. Blots were analysed with NIH Image J 1.42 software.  
 
2.11 Immunofluorescence analysis 
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hCMEC/D3 cells were cultured on Lab-tek glass slides (Thermo Scientific, UK) pre-coated 
with rat tail type I collagen (BD Biosciences, San Jose CA, US), following published protocols 
(9, 23) and using primary antibodies directed against occludin (1:200; Invitrogen) and zonula 
occludens-1 (ZO-1; 1:100; Invitrogen). Nuclei were counterstained with DAPI. Images were 
captured by using a TCS SP5 confocal laser scanning microscope (Leica Microsystems) fitted 
with 405-nm, 488-nm, 594nm and 633-nm lasers, and attached to a Leica DMI6000CS inverted 
microscope fitted with 63X oil immersion objective lens (NA, 1.4 mm, working distance, 0.17 
mm). Images were captured with Leica LAS 2.6.1 software and analysed by using ImageJ 
software (National Institutes of Healths).  
 
2.12 Flow cytometry 
Cells were fixed in 2% (w/v) formaldehyde for 10 minutes at room temperature and then 
washed and resuspended in D-PBS prior to immunofluorescent profiling, as previously 
reported (20, 22). Flow cytometric analysis was performed using a BD FACS Fortessa (BD 
Biosciences); data were analysed using FlowJo software (Treestar Inc, OR, USA). 
 
2.13 shRNA ANXA1 and virus production 
Lentiviral vectors (pLKO.1-puro) bearing validated shRNA sequences directed against human 
ANXA1 (TRC2.0 Mission® shRNA vectors; Sigma-Aldrich, UK) were grown in E.coli and 
purified using Qiagen Miniprep kits (Qiagen Inc, USA) according to manufacturer’s 
instructions. High-titer lentiviral preparations in HEK293T cells and lentiviral infections of 
hCMEC/D3 endothelial cells were produced as described previously (24). Specific clones were 
designated as follows: TRCN0000308208 – shRNA A, TRCN0000296381 – shRNA B and 
TRCN0000296320 – shRNA C. Transduction efficiency and ANXA1 knockdown were 
verified by western blot analysis as previously reported (25). 
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2.14 Real-time polymerase chain reaction 
 RNA was isolated from cells and reverse-transcribed, as described previously (22). Real-time 
polymerase chain reaction was performed using QuantiTect® SYBR green PCR kit (Qiagen, 
Crawley, United Kingdom). Primers directed against ANXA1 (QT00078197) and the control 
genes Rpl32 (QT00046088) and β-actin (QT00095431) coding sequences were purchased from 
Qiagen (QuantiTect® Primer assay; Qiagen, Crawley, United Kingdom). 
 
2.15 Statistical analysis 
Data are expressed as mean ± SEM, with n=3 independent experiments performed in triplicate 
for in vitro studies, and n=8 for in vivo analyses. In all cases, normality of distribution was 
established using the Shapiro-Wilks test, followed by analysis with two-tailed Student’s t-tests 
to compare two groups or for multiple comparison analysis, 1- or 2-way ANOVA followed by 
Tukey’s HSD post hoc tests. A p value of less than 5% was considered significant. 
 
2.16 Ethical Approval 
All animal experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986. Blood samples from healthy volunteers were collected under St 
Thomas’s Hospital Research Ethics Committee (Ref. 07/Q0702/24) and all volunteers gave 
written consent before entering the study. The study has followed established SOPs and the 
experiments were conformed to the principles set out in the WMA Declaration of Helsinki. 
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2 Results 
3.1 Estrogen-dependent sex differences in the BBB response to inflammatory challenge 
We initially characterised the response of the murine BBB to a simple systemic inflammatory 
model, the administration of bacterial lipopolysaccharide (LPS; 3mg/kg i.p.), with assessment 
of barrier permeability through extravasation of intravenous Evan’s blue dye in young adult (2 
month) male and female C57Bl/6 mice. A marked sex difference was notable in male animals 
showing a clear and reproducible, but transient, increase in BBB permeability 4h post-LPS 
administration, whilst such change was not apparent in females (Fig. 1A). Importantly, 
however, reproductively senescent female mice (15 month) responded to systemic LPS in a 
manner analogous to both young and old males, exhibiting significantly enhanced Evan’s blue 
extravasation 4h post-LPS (Fig. 1B).  
 
Given its diverse anti-inflammatory effects (3), estrogen is a major candidate regulator of these 
differential responses to LPS, hence we investigated the role of this hormone in vivo. Young 
adult female mice (2 month) were ovariectomised and subsequently implanted with osmotic 
mini-pumps containing either estradiol (E2) or β-cyclodextrin vehicle (26). Ovariectomy with 
vehicle replacement did not per se increase the degree of basal Evans’ blue dye extravasation, 
but in the presence of LPS (3mg/kg body weight i.p. assessed 4h post-injection) it significantly 
enhanced paracellular permeability (Fig. 1C). Of note, replacement with proestrous levels of 
estradiol completely prevented this effect (Fig. 1C). Furthermore, 24h pre-treatment with 
hrANXA1 via i.v. [0.6µg/kg body weight; Fig. 1C], (16) mirrored the effect of estradiol (E2) 
replacement. 
 
3.2 Estradiol regulation of BBB characteristics and lymphocyte migration in vitro 
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To investigate the cellular and molecular mechanisms behind these in vivo responses we 
utilized the well-established in vitro model of immortalised human microvascular endothelial 
cells, hCMEC/D3 (27). Paracellular permeability of hCMEC/D3 monolayers to 70kDa-FITC 
dextran was significantly enhanced by 24h stimulation with TNFα and IFNγ (10ng/ml 24h; 
Fig. 2A), an effect markedly attenuated by treatment for the last 8h with estradiol (100nM), 
previously selected as optimal dose and time response (Suppl. Fig.1). Similarly, trans-
endothelial electrical resistance of hCMEC/D3 monolayers was significantly reduced by TNFα 
and IFNγ treatment, an effect reversed by estradiol exposure (Fig. 2B). Inter-endothelial tight 
junctions are the principal effectors of the maintenance of the paracellular permeability barrier 
and trans-endothelial resistance; hence we examined the ability of estradiol to modulate two of 
the component proteins of these structures, occludin and zonula occludens-1 (ZO-1). Treatment 
of polarised hCMEC/D3 monolayers grown on transwell filters with TNFα and IFNγ (10ng/ml, 
24h) induced a clear loss of marginal occludin and ZO-1 immunofluorescence, an effect 
reversed by treatment with estradiol (100nM, last 8h; Fig. 2C-D). Together, these data provide 
evidence that inflammation-induced changes in endothelial cell interactions can be countered 
by estradiol, providing a molecular counterpart to the changes seen in the whole animal system. 
 
A major function of the BBB is the regulation of immune cells migration from the circulation 
into the brain parenchyma. To model the effects of estradiol upon this parameter, we studied 
the interaction of human peripheral blood lymphocytes with polarised hCMEC/D3 monolayers 
grown on transwell filters. Inflammatory stimulation (TNFα + IFNγ, 10ng/ml, 24h) of 
hCMEC/D3 cells significantly enhanced numbers of both adherent and transmigrated CD3+ 
lymphocytes, a phenomenon markedly inhibited by pre-treatment of the hCMEC/D3 cells with 
estradiol (100nM, last 8h; Fig. 3A-B). Similar results were obtained using primary murine 
cerebromicrovascular endothelia and T cells (Suppl. Fig. 2). Correlating with these changes in 
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lymphocyte migration, endothelial surface expression of ICAM-1, a cell adhesion molecule 
that is critically required for efficient lymphocyte transmigration (28), was significantly 
enhanced by cytokine stimulation, an effect attenuated by a similar estradiol pre-treatment (Fig. 
3C).  
 
3.3 Estradiol actions are mediated through the BBB regulator ANXA1 
Previously, we described the critical role played by ANXA1 in governing BBB integrity, 
promoting tight junction formation and consequently enhancing inter-endothelial tightness (9). 
As we and others have shown this protein to be transcriptionally modulated by estrogen (11-
13), we investigated the possibility that regulation of ANXA1 underlies the protective effects 
of estradiol upon the BBB (see also Fig.1C). Characterisation of brain microvascular capillary 
ANXA1 content revealed a clear female-dominant sex difference in vessels from young (2 
month) wild-type mice, but also indicated that female vessel ANXA1 expression dramatically 
declined between 2 and 15 month of age (Fig. 4A). Importantly, removal of circulating estrogen 
by ovariectomy significantly lowered cerebral microvascular ANXA1, an effect reversed upon 
estradiol replacement (Fig. 4B). Together, these findings suggest that the effects of aging were 
due at least in part to the reproductive senescence-associated decline in estrogen seen in mice 
(29).  
 
We used an immunoneutralisation strategy (20) to examine the role of ANXA1 in mediating 
the protective effects of estradiol, assessing hCMEC/D3 paracellular permeability. Inclusion 
of an anti-ANXA1 antibody had no effect on TNFα/IFNγ induced paracellular permeability, 
but it was able to block estradiol-induced reversal of this permeability change, an effect not 
seen by addition of the relevant IgG2A isotype control (Fig. 4C). Confirming the position of 
ANXA1 as a mediator of estradiol effects, hCMEC/D3 cells stably transduced with lentivirus-
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borne shRNA sequences targeting ANXA1 (Suppl. Fig. 3) displayed enhanced basal 
paracellular permeability, as shown previously (9). Notably, estradiol was not able to prevent 
the additional increase in permeability seen with TNFα/IFNγ treatment of these cells (Fig. 4D). 
To investigate the contribution of ANXA1 to the control of lymphocyte migration by estradiol 
we first studied the adhesion to and migration across hCMEC/D3 monolayers under-expressing 
ANXA1 (shRNA clones) of human peripheral blood CD3+ lymphocytes. As expected the 
reduction in ANXA1 expression impeded the actions of estrogen in reverting the effects of 
TNFα/IFNγ upon the endothelium (Fig 4E, F). Furthermore, lower expression of ANXA1 per 
se enhanced the impact of TNFα/IFNγ upon ICAM-1 on hCMEC/D3 cells, and moreover 
prevented the modulatory effects of estrogen upon this expression (Fig. 4G). These data 
strongly indicate that the protective actions of estrogen against inflammation-induced BBB 
damage are mediated through modulation of ANXA1 expression. Final validation of the role 
of ANXA1 in the BBB protective effects of estradiol was given through study of sex 
differences in cerebrovascular permeability in ANXA1 null mice (30). As expected, ANXA1 
null mice showed markedly higher basal Evans’ blue extravasation than wild-type animals, 
although surprisingly this was not further raised by treatment with LPS (3mg/kg i.p.); 
importantly however, no signs of sex differences were apparent in any treatment groups (Fig 
4H). 
 
3.4 Receptor-specific roles for ERβ and GPR30 in mediating estrogen actions on the BBB 
To further investigate the mechanisms whereby estradiol could exert these protective effects, 
we examined the potential role of the three main estrogen receptors ERα, ERβ and the G protein 
coupled estrogen receptor GPR30; expression of all three being detectable on hCMEC/D3 cells 
by flow cytometry (Fig. 5A). Using selective estrogen receptor ligands, we assessed the relative 
involvement of the different estrogen receptors in ANXA1 regulation, analysing the 
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membrane-bound pool known to be reflective of secreted ANXA1 (22), and the total 
intracellular pool. Estradiol treatment significantly enhanced membrane-bound ANXA1, an 
effect replicated by the GPR30 agonist G1, but not by either the ERα agonist PPT or the ERβ 
agonist DPN (Fig. 5B). Intriguingly, application of either the ERβ antagonist PHTPP or the 
GPR30 antagonist G15 prevented estradiol-induced up-regulation of membrane-bound 
ANXA1 (Fig. 5B). In contrast, treatment of hCMEC/D3 cells with estradiol or DPN, but neither 
PPT nor G1, increased intracellular ANXA1 content, an effect blocked by PHTPP but not G15 
(Fig. 5C) indicating a role for ERβ in increasing the intracellular pool of ANXA1. Confirming 
that changes in intracellular ANXA1 content were due to de novo synthesis rather than 
secretory block, qRT-PCR analysis of ANXA1 mRNA revealed that either estradiol or DPN, 
but not G1, significantly enhanced ANXA1 mRNA levels, an effect inhibited by PHTPP but 
not G15 (Fig. 5D-E). We have previously shown the importance of ANXA1 N-terminal serine 
phosphorylation for the export and activity of this protein (22) hence we investigated whether 
stimulation of hCMEC/D3 cells with estradiol resulted in serine phosphorylation. Whilst 
estradiol did not appear to induce significant changes in the degree of N-terminal serine 
phosphorylation in cytoplasmic ANXA1, stimulation of hCMEC/D3 cells with the hormone 
induced both rapid (2 minutes) and delayed (8h) phosphorylation of cell surface associated 
ANXA1 (Fig. 5F). Together, these experiments indicate dual, receptor-specific actions of 
estradiol upon ANXA1, namely, the stimulation of protein synthesis via ERβ and the induction 
of N-terminal phosphorylation and subsequent membrane externalisation through GPR30. 
 
We made similar use of estrogen receptor antagonists to define the relative roles of ERβ and 
GPR30 in mediating the regulatory effect of estradiol upon lymphocyte migration. Pre-
incubation of hCMEC/D3 cells with the ERβ antagonist PHTPP completely prevented estradiol 
from reversing TNFα/IFNγ induced CD3+ lymphocyte adhesion (Fig 6A) and transmigration 
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(Fig 6C). Moreover, pre-treatment with the GPR30 antagonist G15 did not modulate the effects 
of estradiol on either lymphocyte adhesion (Fig. 6B) or transmigration (Fig. 6D). We then 
investigated whether blockade of estrogen receptors similarly affected ICAM-1 expression, 
revealing that PHTPP, but not G15, reversed the effects of estradiol upon TNFα/IFNγ-induced 
ICAM-1 up-regulation (Fig. 6E-F), confirming a central role for ERβ in this action. 
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3 Discussion 
Steroid hormones have long been known to possess anti-inflammatory properties, indeed 
synthetic glucocorticoid receptor agonists are amongst the most clinically potent anti-
inflammatory drugs available, but it is only relatively recently that the anti-inflammatory 
potential of estrogen has begun to be closely studied (3). The primary interface between the 
CNS and the inflammatory response, the BBB, has been examined as a target for estrogen 
action (8, 26, 31, 32), but understanding of the molecular pathways governing hormonal 
influence is lacking. Here, we reveal parallel protective effects of estrogen upon the BBB, 
preventing inflammation-induced tight junction breakdown through enhancement of ANXA1 
expression and limiting lymphocyte migration by modulation of endothelial cell ICAM-1. 
Moreover, we reveal for the first time the estrogen receptor subtypes involved in mediating 
these actions, delineating independent but complementary roles for ERβ and GPR30.  
 
An important feature of the current study is that the protective effects of estrogen upon the 
BBB were only discernible in the presence of inflammatory stimuli. In this, estrogen seems to 
act primarily as a homeostatic signal, limiting disturbance and restoring balanced function to 
the BBB, and can thus be truly considered a protective agent. This protective aspect of estrogen 
may go some way to explaining the well-known sex differences in the incidence of major 
cerebrovascular disease, most notably stroke (33, 34), differences that markedly diminish past 
the age of menopause and the associated decline in circulating estrogen (35). Moreover, many 
of the most important risk factors for stroke are inflammatory conditions, e.g. atherosclerosis, 
diabetes, obesity, and it is increasingly evident that the associated high levels of circulating 
cytokines enhance BBB vulnerability, directly contributing to increased stroke risk (36). Our 
finding that the protective effects of estrogen upon the BBB are most apparent following 
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inflammatory challenge may thus at least partly underlie its protective effects in pre-
menopausal women. 
 
In addition to bolstering the evidence for ANXA1 as an estrogen mediator, the current study 
provides the first description of the molecular mechanism whereby these agents interact. The 
primary function of the BBB is to shield the CNS from harmful challenges (37), of which 
inflammatory mediators are an acute example. Our studies thus extend the local pro-resolving 
actions of ANXA1 (38) to the brain, underlining its wider physiological involvement in the 
response to inflammation. Additionally, we have identified a dual, receptor-specific action of 
estrogen upon ANXA1, increasing synthesis via ERβ and modulating ANXA1 post-
translational modification via GPR30. Phosphorylation of ANXA1 is critically required for its 
extracellular export and consequent actions (22), and, whilst identification of the kinase(s) 
responsible lies beyond the scope of this study, suspicion falls upon members of the PKC 
family, as these enzymes are both activated following GPR30 stimulation (39) and can 
phosphorylate ANXA1 (21, 22, 40, 41). 
 
In studying the role of ANXA1 as a mediator of estrogen action, we have also identified a clear 
role for the GPR30 in maintaining BBB integrity under challenge. This receptor is known to 
be expressed on the cerebrovascular endothelium in vivo (42, 43), but as yet evidence for its 
function remains thin. Our data place GPR30 at the centre of the mechanisms responsible for 
preserving the BBB permeability barrier during inflammatory challenge. Moreover, as GPR30 
is a G protein coupled receptor, and thus is activated much more rapidly than the classical 
estrogen receptors ERα and ERβ, it represents a mechanism whereby estrogen can swiftly 
protect the cerebral vasculature following inflammation.  
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The interaction between ANXA1 and estrogen is a major pathway by which the hormone can 
exert an anti-inflammatory, protective effect upon the BBB, affecting not only paracellular 
permeability of circulating molecules but also regulating emigration of lymphocytes into the 
brain. This result is of significance as it represents the first mechanistic explanation of how 
estrogen can limit inflammation-induced cell entry into the brain parenchyma. Lymphocyte 
entry into the brain tissue itself remains a controversial topic, with debate centering on whether 
cells truly pass the glia limitans and interact with neurones directly, or whether they remain in 
the perivascular space (44). Regardless, it is clear that extravasated lymphocytes have the 
potential to sustain or even initiate inflammatory reactions in situ (45), which, given the high 
vulnerability of neurones to inflammatory challenge, poses significant risks for brain tissue 
integrity. Estrogen, through its ability to suppress inflammation-induced endothelial ICAM-1 
upregulation can clearly attenuate lymphocyte migration, further shielding the brain 
parenchyma from peripheral inflammatory insult. Previous studies have indicated a role for 
ERβ in the actions of estrogen on ICAM-1 expression in salivary gland epithelial cells (46) and 
arterial smooth muscle (47), but for the first time we not only extend these findings to the 
endothelial cells of the cerebral vasculature, but provide a clear definition of the next step in 
the pathway downstream of ERβ, namely ANXA1. The question as to how ANXA1 regulates 
ICAM-1 expression requires further study, but may involve an interaction with signalling 
molecules such as AMPK or PPARα (48). 
 
Taken together, our data propose a mechanism of action for estrogen and ANXA1 in the 
modulation of BBB tightness and lymphocyte migration as schematized in figure 7: 1) estradiol 
via GPR30 induces the post-transcriptional modification of ANXA1, which is known to lead 
to its export and consequent autocrine/paracrine induction of BBB tightness pathways; 2) 
estradiol through ERβ blocks lymphocyte adhesion and migration by regulating ICAM-1 
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expression through ANXA1. These combined mechanisms may work together in regulating 
immune cells entry into the brain parenchyma. 
 
In conclusion, our findings identify novel, anti-inflammatory actions of estrogen upon the 
BBB, namely the regulation of inter-endothelial cell permeability and the limitation of 
lymphocyte transmigration. Intriguingly, whilst these two actions appear to be governed in the 
main by different estrogen receptors, with GPR30 regulating paracellular permeability and 
ERβ limiting lymphocyte migration through suppression of ICAM-1 expression, these actions 
are both mediated by the downstream protein ANXA1, highlighting the significance of this 
protein in the BBB. Together, these harmonizing pathways represent clear mechanisms through 
which estrogen can aid the maintenance of BBB homeostasis in the face of inflammatory 
challenge.  
 
4 Conclusions 
The prevalence of inflammatory cerebrovascular diseases shows a distinct male predominance, 
with numerous studies showing women to be relatively protected. Understanding why this is 
the case remains a challenge. Here, we identify a powerful protective action of the female sex 
steroid estrogen, showing that this hormone can both enhance inter-endothelial cell tight 
junction function and limit lymphocyte extravasation following challenge with inflammatory 
cytokines. Moreover, we identify these actions as being mediated through upregulation of the 
potent anti-inflammatory and blood-brain barrier regulating protein annexin A1. Together our 
data offer a novel mechanism whereby estrogen can protect the brain from insult, and suggest 
an innovative pathway for therapeutic targeting in cerebrovascular disease.  
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Figure Legends 
 
Figure 1 Estradiol protects against inflammation-induced BBB integrity defects. A 
Extravasation of Evan’s blue dye into brain parenchyma over a one hour period in two month 
old male and female C57Bl/6 mice (n=8) following i.p. injection of saline or LPS (3mg/kg 
body weight) for 4h, 24h or 7 days, data are mean ± SEM, *p<0.05 vs. same sex saline control. 
B Extravasation of Evan’s blue dye into brain parenchyma over a one hour period in young (2 
month) and old (15 month) male and female C57Bl/6 mice (n=8) 4h following i.p. injection of 
LPS (3 mg/kg body weight) or 100µl saline vehicle.; data are expressed as mean ± SEM, 
*p<0.05 vs. 2 month, same sex saline control. C Extravasation of Evan’s blue dye into the brain 
parenchyma over a three hour period in sham operated or ovariectomised female C57Bl/6 mice 
(2 month; n=8) receiving 14 days treatment with either estradiol (2µg/kg/day) or β-
cyclodextrin, or receiving a single i.v. injection of hrANXA1 (0.6µg/kg); data are mean ± SEM, 
*p<0.05 vs. saline control, +p<0.05 vs. OVX-vehicle treated.  
 
Figure 2 Estradiol prevents cytokine-induced disruption of BBB endothelial permeability 
characteristics and tight junction component subcellular distribution. A Assessment of 
the paracellular permeability of hCMEC/D3 monolayers to 70kDa FITC-dextran following 
treatment for 24h with TNFα + IFNγ (both 10ng/ml), with or without inclusion of 100nM 
estradiol for the last 8 hours of incubation; data are mean ± SEM, n=3 (three independent 
experiments performed each in triplicate), *p<0.05 vs. unstimulated control, +p<0.05 vs. 
TNFα/IFNγ treatment control. B Trans-endothelial electrical resistance of hCMEC/D3 
monolayers following treatment for 24h with TNFα + IFNγ (both 10ng/ml), with or without 
inclusion of 100nM estradiol for the last 8 hours of incubation; data are mean ± SEM, n=3 
(three independent experiments performed each in triplicate), *p<0.05 vs. unstimulated control, 
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+p<0.05 vs. TNFα/IFNγ treatment control C Representative confocal microscopic analysis of 
hCMEC/D3 monolayer occludin expression following treatment for 24h with TNFα + IFNγ 
(both 10ng/ml), with or without inclusion of 100nM estradiol for the last 8 hours of incubation; 
arrowheads indicate the presence or absence of peripheral occludin staining with different 
treatments; data are representative of three independent experiments. D Confocal microscopic 
analysis of hCMEC/D3 monolayer ZO-1 expression following treatment for 24h with TNFα + 
IFNγ (both 10ng/ml), with or without inclusion of 100nM estradiol for the last 8 hours of 
incubation; arrowheads indicate the presence or absence of peripheral ZO-1 staining with 
different treatments; data are representative of three independent experiments. 
 
Figure 3 Estradiol prevents peripheral blood lymphocyte migration across an inflamed 
endothelium and prevents inflammatory cytokines induced up-regulation of ICAM-1. A 
Adhesion of CD3+ lymphocytes to hCMEC/D3 monolayers following treatment with TNFα + 
IFNγ (both 10ng/ml) and/or estradiol (100nM). Data are mean ± SEM, n=3 (three independent 
experiments performed each in triplicate), *p<0.05 vs. unstimulated control, +p<0.05 vs. 
TNFα/IFNγ treatment alone. B Transmigration of CD3+ lymphocytes across hCMEC/D3 
monolayers following treatment with TNFα + IFNγ (both 10ng/ml) and/or estradiol (100nM). 
Data are mean ± SEM, n=3 (three independent experiments performed each in triplicate), 
*p<0.05 vs. unstimulated control, +p<0.05 vs. TNFα/IFNγ treatment alone. C Expression of 
ICAM-1 on the cell surface of hCMEC/D3 monolayers following treatment with TNFα + IFNγ 
(both 10ng/ml) and/or estradiol (100nM) data are mean ± SEM, n=3 (three independent 
experiments performed each in triplicate), *p<0.05 vs. unstimulated control, +p<0.05 vs. 
TNFα/IFNγ treatment alone. 
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Figure 4 Protection of BBB integrity by estradiol is dependent upon the tight junction 
regulator ANXA1. A Expression of ANXA1 in cerebral capillary endothelia from male (2 
month) and female (2 and 15 month) C57Bl/6 mice assessed by western blot; data are mean ± 
SEM, n=8, *p<0.05 vs. male, +p<0.05 vs. young female. B Expression of ANXA1 in cerebral 
capillary endothelia from ovariectomised C57Bl/6 mice treated with PEG-400 vehicle or 
estradiol (2µg/kg/day) assessed by western blot; data are mean ± SEM, n=8, *p<0.05 vs. OVX 
+ vehicle, +p<0.05 vs. OVX + E2. C Inclusion of a neutralizing anti-ANXA1 antibody, but not 
its IgG2A control, blocks the ability of estradiol to reverse the cytokine-induced enhancement 
of paracellular permeability; data are mean ± SEM, n=3 (three independent experiments 
performed each in triplicate), *p<0.05 vs. unstimulated cells. D Stable infection of hCMEC/D3 
cells with an shRNA-lentivirus construct targeting ANXA1 limits the ability of estradiol to 
reverse TNFα/IFNγ-induced paracellular permeability; data are mean ± SEM, n=3 
(independent experiments performed each in triplicate), *p<0.05 vs. unstimulated cells, 
+p<0.05 vs. TNFα/IFNγ alone. E-F Adherent (E) and transmigrated (F) CD3+ lymphocytes 
following 4h co-incubation of human PBMCs and hCMEC/D3 monolayers stably infected with 
an shRNA construct targeting ANXA1, previously treated for 24h with TNFα + IFNγ (both 
10ng/ml), with or without inclusion of 100nM estradiol for the last 8 hours of incubation; data 
are mean ± SEM, n=3 (three independent experiments performed each in triplicate), *p<0.05 
vs. unstimulated control, +p<0.05 vs. TNFα/IFNγ treatment alone. G Stable infection of 
hCMEC/D3 cells with an shRNA construct targeting ANXA1 affected the ability of estradiol 
to reverse TNFα/IFNγ-induced increases in cell surface ICAM-1 expression; data are mean ± 
SEM, n=3 (three independent experiments performed each in triplicate), *p<0.05 vs. 
unstimulated cells, +p<0.05 vs. TNFα/IFNγ alone. H Extravasation of Evan’s blue dye into 
brain parenchyma over a one hour period in two month old male and female AnxA1-/- mice 
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(n=8) following i.p. injection of saline or LPS (3mg/kg body weight) for 4h, 24h or 7 days, 
data are mean ± SEM. 
 
Figure 5 Estradiol promotes ANXA1 production via ERβ and export via GPR30. A Flow 
cytometry analysis of ERα, ERβ and GPR30 expression in hCMEC/D3 cells; histograms are 
composed of 10000 events. B Membrane-bound ANXA1, measured by ELISA, from 
hCMEC/D3 monolayers treated for 8h with the estrogen receptor agonists Estradiol (E2, 
100nM), PPT (200pM), DPN (850pM) or G1 (2nM) or with a combination of the estrogen 
receptor antagonists PHTPP (140nM) or G15 (20nM) with estradiol (E2, 100nM); data are 
mean ± SEM, n=3 (three independent experiments performed each in triplicate), *p<0.05 vs. 
untreated cells, +p<0.05 vs. cells treated with estradiol alone. C Intracellular ANXA1 in 
hCMEC/D3 monolayers treated for 8h with the estrogen receptor agonists estradiol (100nM), 
PPT (200pM), DPN (850pM) or G1 (2nM) or with a combination of the estrogen receptor 
antagonists PHTPP (140nM) or G15 (20nM) with estradiol (100nM); data are mean + SEM, 
n=3 (three independent experiments performed each in triplicate), *p<0.05 vs. untreated cells, 
+p<0.05 vs. cells treated with estradiol alone. D Quantitative RT-PCR analysis of ANXA1 
mRNA expression (corrected to the housekeeping gene Rpl32) in hCMEC/D3 monolayers 
treated for 8h with estradiol (100nM), DPN (850pM) or G1 (2nM); data are mean ± SEM, n=3 
(three independent experiments performed each in triplicate) *p<0.05 vs. untreated cells. E 
Quantitative RT-PCR analysis of ANXA1 mRNA expression in hCMEC/D3 monolayers treated 
for 8h with estradiol (100nM), with or without pre-treatment for 30 minutes with the estrogen 
receptor antagonists PHTPP (140nM) or G15 (20nM); data are mean ± SEM, n=3 (three 
independent experiment performed each in triplicate), *p<0.05 vs. untreated cells. F Typical 
western blot analysis of total and N-terminal serine-phosphorylated ANXA1 content in 
intracellular and membrane fractions of hCMEC/D3 monolayers treated for 0, 2, 5, 10 or 30 
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minutes or 8 hours with 100nM estradiol, alongside GAPDH loading controls; presented blots 
are representative of 3 independent experiments. 
 
Figure 6 Estradiol regulates CD3+ lymphocyte adhesion and migration and ICAM-1 
expression via ERβ. A Pre-incubation of hCMEC/D3 monolayers with the ERβ antagonist 
PHTPP prevents the reversal of TNFα/IFNγ-induced CD3+ lymphocyte adhesion afforded by 
incubation with estradiol in untreated cells; data are mean ± SEM, n=3 (three independent 
experiments performed each in triplicate), *p<0.05 vs. control, +p<0.05 vs. TNFα/INFγ 
treatment alone. B Pre-incubation of hCMEC/D3 monolayers with the GPR30 antagonist G15 
did not change how estradiol affected CD3+ lymphocyte adhesion induced by TNFα/INFγ; data 
are mean ± SEM, n=3 (three independent experiments performed each in triplicate), *p<0.05 
vs. control, +p<0.05 vs. TNFα/IFNγ treatment alone. C Pre-incubation of hCMEC/D3 
monolayers with the ERβ antagonist PHTPP prevented the reversal of TNFα/IFNγ-induced 
CD3+ lymphocyte transmigration afforded by incubation with estradiol in untreated cells, data 
are mean ± SEM, n=3 (three independent experiments performed each in triplicate), *p<0.05 
vs. control, +p<0.05 vs. TNFα/IFNγ treatment alone. D Pre-incubation of hCMEC/D3 
monolayers with the GPR30 antagonist G15 did not affect the reversal of TNFα/IFNγ-induced 
CD3+ lymphocyte transmigration afforded by incubation with estradiol, data are mean ± SEM, 
n=3 (three independent experiments performed each in triplicate), *p<0.05 vs. control, +p<0.05 
vs. TNFα/IFNγ treatment alone. E Pre-incubation of hCMEC/D3 monolayers with the ERβ 
antagonist PHTPP inhibited the reversal of TNFα/IFNγ-induced cell surface ICAM-1 up-
regulation afforded by incubation of untreated cells with estradiol, data are mean ± SEM, n=3 
(three independent experiments performed each in triplicate), *p<0.05 vs. control, +p<0.05 vs. 
TNFα/IFNγ treatment alone. F Pre-incubation of hCMEC/D3 monolayers with the GPR30 
antagonist G15 did not affect the reversal of TNFα/IFNγ-induced cell surface ICAM-1 up-
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regulation afforded by incubation with estradiol, data are mean ± SEM, n=3 (three independent 
experiments each performed in triplicate), *p<0.05 vs. control, +p<0.05 vs. TNFα/IFNγ 
treatment alone. 
 
Figure 7 Schematic representations of potential mechanisms of action of Estradiol in 
protecting the brain against neuroinflammation. 1) Estradiol binds to its membrane-bound 
receptor GPR30 promoting ANXA1 phosphorylation. Once phosphorylated, ANXA1 can bind 
to its specific receptor FPR2 (as shown in (9)) and enhance the stabilization of tight junctions 
via modulation of the actin cytoskeleton. 2) Under inflammatory conditions, estradiol binds to 
its nuclear receptor ERβ enhancing ANXA1 transcription, which can then trigger a down-
modulation of ICAM-1 expression. As ICAM-1 is necessary for endothelium-leukocyte 
interplay, reduced expression attenuates leukocyte adhesion and transmigration. 
 
Supplemental Figure 1 Estradiol promotes hCMEC/D3 cell ANXA1 production in a dose- 
and time-dependent manner. A Total cellular ANXA1 content in hCMEC/D3 monolayers 
incubated with increasing concentrations of estradiol for 8 hours; data are mean ± SEM, n=3 
(three independent experiments performed each in triplicate) , *p<0.05 vs. untreated cells. B 
Total cellular ANXA1 content in hCMEC/D3 monolayers incubated with 100nM estradiol for 
increasing periods of time; data are mean ± SEM, n= 3 (three independent experiments 
performed each in triplicate), *p<0.05 vs. untreated cells. 
 
Supplemental Figure 2 Estradiol prevents murine T cells adhesion and migration across 
primary brain microvascular endothelial cells. A Adhesion of murine CD3+ lymphocytes to 
primary brain microvascular endothelial cells following treatment with TNFα + IFNγ (both 
10ng/ml) and/or estradiol (100nM). Data are mean ± SEM, n=3 (three independent 
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experiments, each performed in triplicate), *p<0.05 vs. unstimulated control, +p<0.05 vs. 
TNFα/IFNγ treatment alone. B Transmigration of murine CD3+ lymphocytes across primary 
brain microvascular endothelial cells following treatment with TNFα + IFNγ (both 10ng/ml) 
and/or estradiol (100nM). Data are mean ± SEM, n=3 (three independent experiments, each 
performed in triplicate), *p<0.05 vs. unstimulated control, +p<0.05 vs. TNFα/IFNγ treatment 
alone.  
 
Supplemental Figure 3 Validation of down regulation of ANXA1 expression in 
hCMEC/D3 cells following infection with shRNA. Representative western blot for selected 
clones (A-C) showing down-regulation of ANXA1 expression compared with mock infected 
cells (U) following stable infection with shRNA sequences targeting ANXA1. 
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